Cluster headache: an update on clinical features, epidemiology, pathophysiology, diagnosis, and treatment.

Cluster headache (CH) is one of the worst primary headaches that remain underdiagnosed and inappropriately treated. There are recent advances in the understanding of this disease and available treatments. This paper aims to review CH's recent clinical and pathophysiological findings, diagnosis, and treatment. We performed a narrative literature review on the socio-demographics, clinical presentations, pathophysiological findings, and diagnosis and treatment of CH. CH affects 0.1% of the population with an incidence of 2.07-9.8/100,00 person-years-habitants, a mean prevalence of 53/100,000 inhabitants (3-150/100,000 inhabitants). The male-to-female ratio remains inconclusive, as the ratio of 4.3:1 has recently been modified to 1.3-2.6, possibly due to previous misdiagnosis in women. Episodic presentation is the most frequent (80%). It is a polygenetic and multifactorial entity that involves dysfunction of the trigeminovascular system, the trigeminal autonomic reflex, and the hypothalamic networks. An MRI of the brain is mandatory to exclude secondary etiologies. There are effective and safe pharmacological treatments oxygen, sphenopalatine, and great occipital nerve block, with the heterogeneity of clinical trial designs for patients with CH divided into acute, transitional, or bridge treatment (prednisone) and preventive interventions. In conclusion, CH remains underdiagnosed, mainly due to a lack of awareness within the medical community, frequently causing a long delay in reaching a final diagnosis. Recent advances in understanding the principal risk factors and underlying pathophysiology exist. There are new therapeutic possibilities that are effective for CH. Indeed, a better understanding of this challenging pathology will continue to be a subject of research, study, and discoveries in its diagnostic and therapeutic approach.

Cluster headache: state of the art in treatment.

Cluster headache (CH) is the most common and devastating autonomic headache with multiple and recent advances in treatment. However, it usually goes unrecognized and is found to have a delayed and inappropriate treatment. This paper aims to review the current therapeutic options for patients with CH. We conducted a narrative literature review on the treatments available for this condition using the American Academy of Neurology (AAN) classification of therapeutic evidence. We found effective and safe pharmacological and non-pharmacological therapies with heterogeneity of clinical trial designs for patients with CH, and they are divided into three phases, namely, transitional, acute, and preventive interventions. Prednisone (A) is the most studied treatment in the transitional phase; acute attacks are treated using triptans (A), oxygen (A), and non-invasive transcutaneous vagal nerve stimulation (A). Verapamil (A) and monoclonal antibodies (possible A) are considered the first options in preventive treatments, followed by multiple pharmacological and non-pharmacological options in prophylactic treatments. In conclusion, numerous effective and safe treatments are available in treating patients with episodic, chronic, and pharmacoresistant CH according to the clinical profile of each patient.

Dapsone, More than an Effective Neuro and Cytoprotective Drug.

BACKGROUND: Dapsone (4,4'-diamino-diphenyl sulfone) is a synthetic derivative of sulfones, with the antimicrobial activity described since 1937. It is also a drug traditionally used in dermatological therapies due to its anti-inflammatory effect. In recent years its antioxidant, antiexcitotoxic, and antiapoptotic effects have been described in different ischemic damage models, traumatic damage, and models of neurodegenerative diseases, such as Parkinson's (PD) and Alzheimer's diseases (AD). Finally, dapsone has proven to be a safe and effective drug as a protector against heart, renal and pulmonary cells damage; that is why it is now employed in clinical trials with patients as a neuroprotective therapy by regulating the main mechanisms of damage that lead to cell death ObjectiveThe objective of this study is to provide a descriptive review of the evidence demonstrating the safety and therapeutic benefit of dapsone treatment, evaluated in animal studies and various human clinical trials Methods: We conducted a review of PubMed databases looking for scientific research in animals and humans, oriented to demonstrate the effect of dapsone on regulating and reducing the main mechanisms of damage that lead to cell death ConclusionThe evidence presented in this review shows that dapsone is a safe and effective neuro and cytoprotective treatment that should be considered for translational therapy.

Comparative study of cardiac function between two populations in Latin America using the transthoracic echocardiogram: Atahualpa, Ecuador, and Mexico City, Mexico.

Objetivo: Comprobar las diferencias morfológicas y funcionales del corazón en dos poblaciones latinoamericanas con distintas características raciales y condiciones de vida. Métodos: Mediante el ecocardiograma transtorácico se obtuvieron datos de 206 personas: 103 del poblado de Atahualpa, Ecuador (nivel del mar, edad x̄ 75 ± 4.2 años, 53 mujeres) y 103 habitantes de la Ciudad de México (altitud de 2,300 m, edad x̄ 75 ± 4.2 años, 52 mujeres). Resultados: Las diferencias significativas entre Atahualpa y la Ciudad de México fueron frecuencia cardíaca, 66 vs. 80; diámetro diastólico ventricular izquierdo, 40.8 vs. 42.7; grosor del tabique, 9.8 vs. 11.6; pared posterior, 10.2 vs. 11.8; volumen-latido en centímetros cúbicos, 53.0 vs. 46.6; volumen auricular Izquierdo, 25.8 vs. 33.6; presión sistólica de la arteria pulmonar, 27.1 vs. 42.0; gasto cardíaco, 3.1 vs. 4.8; cociente E/Ea, 6.4 vs. 9.2; área mitral, 3.4 vs. 3.0. El comparativo de la función diastólica entre Atahualpa y la Ciudad de México fue: tipo 0: 2 vs. 1; tipo 1: 96 vs. 81; tipo 2: 5 vs. 20; tipo 3: 0 vs. 1. Conclusión: Las características ecocardiográficas que identifican los cambios adaptativos del corazón en Atahualpa coinciden con personas que viven a nivel del mar y con buena actividad física y en México con los habitantes de grandes altitudes y expuestos a contaminación ambiental. La función sistólica del ventrículo izquierdo fue similar en ambas poblaciones, lo que indica que los cambios adaptativos hacen posible que el corazón sea eficaz en diferentes circunstancias del ecosistema. Objective: To compare morphological and functional differences of the heart in two Latin American populations with different ethnicity and living conditions. Methods: Using transthoracic echocardiogram we obtained data on 206 individuals: 103 from Atahualpa, Ecuador (living at sea level, mean age: 75 ± 4.2 years, 53 women) and 103 inhabitants from Mexico City (living at 2300 m above sea level, mean age: 75 ± 4.2 years, 52 women). Results: Significant differences between Atahualpa and Mexico were: Heart rate 66 versus 80 x', left ventricular diastolic diameter 40.8 versus 42.7, septum thickness 9.8 versus 11.6, posterior wall 10.2 versus 11.8, stroke volume cc 53.0 versus 46.6, left atrial volume 25. 8 versus 33.6, systolic pressure of the pulmonary artery 27.1 versus 42.0, cardiac output 3.1 versus 4.8, E/Ea ratio 6.4 versus 9.2, and mitral area 3.4 versus 3.0. Comparison of diastolic function between Atahualpa and Mexico was: Type 0; 2 versus 1. Type 1; 96 versus 81. Type 2; 5 versus 20 and Type 3; 0 versus 1. Conclusion: Echocardiographic characteristics that identify adaptive changes of the heart in Atahualpa are coincident with people living at sea level and with good physical activity, and Mexico City, with inhabitants living at high altitudes and exposed to environmental pollution. The systolic function of the left ventricle was similar in both populations, indicating that adaptive changes allow the heart to be effective in different circumstances of the ecosystem.

Estudio comparativo de la función cardíaca en dos poblaciones de América Latina mediante el ecocardiograma transtorácico: Atahualpa, Ecuador y Ciudad de México, México / Comparative study of cardiac function between two populations in Latin America using the transthoracic echocardiogram: Atahualpa, Ecuador, and Mexico City, Mexico

Resumen Objetivo: Comprobar las diferencias morfológicas y funcionales del corazón en dos poblaciones latinoamericanas con distintas características raciales y condiciones de vida. Métodos: Mediante el ecocardiograma transtorácico se obtuvieron datos de 206 personas: 103 del poblado de Atahualpa, Ecuador (nivel del mar, edad x̄ 75 ± 4.2 años, 53 mujeres) y 103 habitantes de la Ciudad de México (altitud de 2,300 m, edad x̄ 75 ± 4.2 años, 52 mujeres). Resultados: Las diferencias significativas entre Atahualpa y la Ciudad de México fueron frecuencia cardíaca, 66 vs. 80; diámetro diastólico ventricular izquierdo, 40.8 vs. 42.7; grosor del tabique, 9.8 vs. 11.6; pared posterior, 10.2 vs. 11.8; volumen-latido en centímetros cúbicos, 53.0 vs. 46.6; volumen auricular Izquierdo, 25.8 vs. 33.6; presión sistólica de la arteria pulmonar, 27.1 vs. 42.0; gasto cardíaco, 3.1 vs. 4.8; cociente E/Ea, 6.4 vs. 9.2; área mitral, 3.4 vs. 3.0. El comparativo de la función diastólica entre Atahualpa y la Ciudad de México fue: tipo 0: 2 vs. 1; tipo 1: 96 vs. 81; tipo 2: 5 vs. 20; tipo 3: 0 vs. 1. Conclusión: Las características ecocardiográficas que identifican los cambios adaptativos del corazón en Atahualpa coinciden con personas que viven a nivel del mar y con buena actividad física y en México con los habitantes de grandes altitudes y expuestos a contaminación ambiental. La función sistólica del ventrículo izquierdo fue similar en ambas poblaciones, lo que indica que los cambios adaptativos hacen posible que el corazón sea eficaz en diferentes circunstancias del ecosistema.

Abstract Objective: To compare morphological and functional differences of the heart in two Latin American populations with different ethnicity and living conditions. Methods: Using transthoracic echocardiogram we obtained data on 206 individuals: 103 from Atahualpa, Ecuador (living at sea level, mean age: 75 ± 4.2 years, 53 women) and 103 inhabitants from Mexico City (living at 2300 m above sea level, mean age: 75 ± 4.2 years, 52 women). Results: Significant differences between Atahualpa and Mexico were: Heart rate 66 versus 80 x’, left ventricular diastolic diameter 40.8 versus 42.7, septum thickness 9.8 versus 11.6, posterior wall 10.2 versus 11.8, stroke volume cc 53.0 versus 46.6, left atrial volume 25. 8 versus 33.6, systolic pressure of the pulmonary artery 27.1 versus 42.0, cardiac output 3.1 versus 4.8, E/Ea ratio 6.4 versus 9.2, and mitral area 3.4 versus 3.0. Comparison of diastolic function between Atahualpa and Mexico was: Type 0; 2 versus 1. Type 1; 96 versus 81. Type 2; 5 versus 20 and Type 3; 0 versus 1. Conclusion: Echocardiographic characteristics that identify adaptive changes of the heart in Atahualpa are coincident with people living at sea level and with good physical activity, and Mexico City, with inhabitants living at high altitudes and exposed to environmental pollution. The systolic function of the left ventricle was similar in both populations, indicating that adaptive changes allow the heart to be effective in different circumstances of the ecosystem.

Feasibility of a new free mobility procedure to evaluate the function of the autonomic nervous system in patients with syncope.

To propose a new test to evaluate the autonomic nervous system in patients with syncope: Multimodal Monitoring for Diagnosis of Dysautonomia (MMDD). We included 21 patients with syncope (16 female, 6 male, mean age 43.5 years) and 21 with no-syncope subjects (15 female, 7 male, mean age 45.1 years) to perform a test of nine 2-min stages: four while resting and four during active testing of autonomic response. Transcranial-Doppler, electrocardiogram, and photoplethysmography blood pressure pulse-to-pulse monitoring, allow registering six variables from the Middle Cerebral Artery and four from the Cardiovascular System. We analyze each variable's mean differences in each stage and its change when they pass from one stage to another with the T and Z tests. To understand the significance of the change, we use a logistic regression model for a certain subgroup of variables. Since we have a small dataset, we use the bootstrap technique to infer the general behavior that characterizes a syncope. Our data confirm differences between syncope and non-syncope patients during MMDD stress stages 2, 4, 6 and 8. Bootstrap and multivariate logistic regression allow us to identify which sets of variables in each of these stages of the MMDD are sufficiently sensitive to recognizing syncope. MMDD protocol can recognize a syncope patient with some confidence by detecting subtle changes in the autonomic nervous system. This protocol encourages us to continue to study the effectiveness of MMDD protocol allowing a new approach to future research.

Cerebral hemodynamics in the non-alcoholic fatty liver.

INTRODUCTION AND OBJECTIVES: The association between non-alcoholic fatty liver disease and cerebral hemodynamics arises from cardiovascular damage mechanisms such as endothelial dysfunction, arterial wall increased stiffness, high thickness of the intimate index of the internal carotid artery, left ventricular hypertrophy, left diastolic dysfunction, calcification coronary arteries and increased epicardial fat. The multidirectional relationship between systemic inflammation and lipid metabolism constitutes a common and simultaneous mechanism that causes vascular damage. This study aims to provide insight into the relationship between non-alcoholic fatty liver disease and the function of systemic circulation and cerebral circulation using Doppler ultrasound. PATIENTS AND METHODS: Is an observational, cross-sectional, prospective, comparative study conducted at Medica Sur Hospital. Thirty-five patients were selected consecutively. The patients consulted neurological service for various symptoms without severity criteria, such as vertigo, primary headache and balance disturbances. RESULTS: There is a difference in the variables mean of the right MCA PI (p = 0.023), left MCA PI" (p = 0.004), and left VA PI (p = 0.036) between the control and NAFLD groups. The correlation analysis between these variables and the CAP showed a positive correlation of the three variables with the CAP, "right MCA PI" (r = 0.384), left MCA PI "(r = 0.509) and" left VA PI " (r = 0.551). CONCLUSIONS: This study demonstrates a subclinical process of the middle cerebral artery in subjects with NAFLD, which suggests it may be involved in the disease development and points the need to make decisions for this liver manifestation prevention and treatment.

Consenso multidisciplinario de diagnóstico y tratamiento del dolor neuropático periférico y localizado en México.

Neuropathic pain is an entity that causes patient disability and its diagnosis and treatment is a challenge for physicians. In a significant percentage of patients with neuropathic pain, it is restricted to one dermatome or to a particular region of the body; in this case, it is referred to as localized neuropathic pain. There are no Mexican clinical guidelines proposing recommendations for the diagnosis and treatment of localized neuropathic pain in our population. This article presents the recommendations of a multidisciplinary consensus of specialists from different areas involved in the diagnosis and treatment of this type of patients.

El dolor neuropático es una entidad que provoca discapacidad al paciente y su diagnóstico y tratamiento es un reto para los médicos. En un porcentaje importante de pacientes afectados, el dolor neuropático se presenta circunscrito a un dermatoma o a una región concreta del cuerpo, denominándose en ese caso dolor neuropático localizado. No existen guías clínicas mexicanas que postulen recomendaciones para el diagnóstico y tratamiento del dolor neuropático localizado en nuestra población. En este artículo se exponen las recomendaciones de un consenso multidisciplinario realizado con especialistas de distintas áreas implicadas en el diagnóstico y tratamiento de este tipo de pacientes.

Consenso multidisciplinario de diagnóstico y tratamiento del dolor neuropático periférico y localizado en México / Multidisciplinary consensus on diagnosis and treatment of peripheral and localized neuropathic pain in Mexico

Resumen El dolor neuropático es una entidad que provoca discapacidad al paciente y su diagnóstico y tratamiento es un reto para los médicos. En un porcentaje importante de pacientes afectados, el dolor neuropático se presenta circunscrito a un dermatoma o a una región concreta del cuerpo, denominándose en ese caso dolor neuropático localizado. No existen guías clínicas mexicanas que postulen recomendaciones para el diagnóstico y tratamiento del dolor neuropático localizado en nuestra población. En este artículo se exponen las recomendaciones de un consenso multidisciplinario realizado con especialistas de distintas áreas implicadas en el diagnóstico y tratamiento de este tipo de pacientes.

Abstract Neuropathic pain is an entity that causes patient disability and its diagnosis and treatment is a challenge for physicians. In a significant percentage of patients with neuropathic pain, it is restricted to one dermatome or to a particular region of the body; in this case, it is referred to as localized neuropathic pain. There are no Mexican clinical guidelines proposing recommendations for the diagnosis and treatment of localized neuropathic pain in our population. This article presents the recommendations of a multidisciplinary consensus of specialists from different areas involved in the diagnosis and treatment of this type of patients.

Early diagnosis of Balo's concentric sclerosis by diffusion tensor tractography: a case report and literature review.

Balo concentric sclerosis is an infrequent variant of a demyelinating disease related to multiple sclerosis, initially thought to have an acute presentation and a fatal outcome. Recent studies have reported non-fatal forms of Balo concentric sclerosis, focusing on the importance of early diagnosis using magnetic resonance imaging (MRI), along with spectroscopy and diffusion/perfusion sequences. Recently, we have been able to draw a three-dimensional image of a specific bundle of fibers by means of a diffusion tensor technique of the magnetic resonance imaging tractography (t-MRI). We report the case of a young woman presenting with acute and progressive focal neurological symptoms, including right body paresis, whose diagnosis was suggested by MRI and confirmed by pathology to be Balo concentric sclerosis. She was treated with boluses of methylprednisolone, achieving full neurological remission one year after admission. This is, to our knowledge, the first report describing the use of t-MRI for diagnosing BCS. We consider that t-MRI will allow, in a near future, early diagnosis of the disease, its prompt treatment, and establishing new classification criteria. This case confirms the existence of benign forms of Balo concentric sclerosis with a good response to steroid therapy, where functional recovery is possible.

La esclerosis concéntrica de Baló es una variante infrecuente de enfermedad desmielinizante relacionada con la esclerosis múltiple, inicialmente considerada de progresión fatal. En estudios recientes se reportan variantes no fatales de esclerosis concéntrica de Baló en los que se enfatiza la importancia del diagnóstico por medio de la imagen por resonancia magnética, utilizando además la espectroscopia y las secuencias de difusión y perfusión. En los últimos años se ha logrado reproducir la imagen tridimensional de un fascículo en particular y observar la presencia de lesiones por medio de la tractografía por imagen por resonancia magnética mediante la técnica de tensor de difusión. Presentamos el caso de una mujer joven con síntomas neurológicos focales agudos, incluyendo paresia de extremidades derechas, cuyo diagnóstico por biopsia fue de esclerosis concéntrica de Baló, confirmando el resultado de los estudios de imagen. La paciente recibió tratamiento con bolos de metilprednisolona, obteniendo remisión clínica completa a largo plazo. A nuestro entender, este es el primer reporte que describe los hallazgos de la esclerosis concéntrica de Baló utilizando la técnica de tensor de difusión. Consideramos que dicha técnica permitirá en el futuro la detección temprana de la enfermedad, su tratamiento oportuno y permitirá establecer nuevos criterios de clasificación y estratificación. Este caso demuestra la existencia de variantes benignas de esclerosis concéntrica de Baló, que tienen buena respuesta a la terapia con glucocorticoides y donde se logra la recuperación funcional.

Neuroprotective effect of dapsone in patients with acute ischemic stroke: a pilot study.

OBJECTIVES: In a previous study of brain ischemia in rats, dapsone (4,4'-diamino-diphenylsulfone) was associated with a neuroprotective effect. As dapsone is safe and relatively free of adverse reactions, we conducted a pilot clinical trial to assess the possibility of using this drug in patients with a cerebral infarction. METHODS: A double-blind, placebo-controlled, pilot clinical trial of dapsone was conducted from January 1999 to January 2000. Thirty patients with a CT or MRI documented ischemic stroke in the territory of the middle cerebral artery were included. Patients with >4 points of the National Institute of Health Stroke Scale (NIHSS) were randomly allocated to receive either a single dose of 200 mg dapsone or placebo. For follow-up, NIHSS on days 0, 2, 7 and 60, modified Rankin scale and Barthel index at day 60 were applied. Adverse reactions were also recorded. The main cut point was considered when a patient obtained a variation of 2 points for modified Rankin scale and 17 points for Barthel index. RESULTS: Fifteen patients received dapsone and 15 received placebo. Twenty-nine were followed up for 60 days and one patient in the treatment group died during follow-up. Favorable scores were achieved for treated patients by all different measures; NIHSS (p=0.032), Barthel (p=0.049) and Rankin scale (RR=0.182, 95% CI: 0.04 and 0.86). Best results were obtained when treatment started within the first 8-10 hours after stroke. No adverse reactions related to medication were reported. DISCUSSION: Dapsone appears as a useful and safe drug for the treatment of stroke patients. Results of this pilot trial are promising and support further research to define the role of dapsone as a neuroprotective drug.

Frequency of delirium in a neurological emergency room.

The authors present a cross-sectional survey designed to evaluate the presence of delirium in patients with neurological emergencies. Two hundred and two patients were included in the study: 14.9% of subjects had delirium; 62.4% had no arousal disturbances; and 22.7% presented a coma or stupor state. Findings revealed that the presence of a cerebral infection, the presence of multiple etiologies, and the location of lesions in the frontal and temporal lobes were all associated with delirium. Results substantiate that delirium is a frequent occurrence in neurological patients and that the presence of multiple etiologies must be investigated in each patient.

EGP-314 is expressed differentially in three brain zones at an early time in an experimentally induced ischemia rat model.

Gene expression in frontal, occipital, and hippocampal regions of rat brains at 15 min of ischemic injury was studied in a rat model by producing focal cerebral ischemia through middle cerebral artery (MCA) occlusion without reperfusion. Catalase, epithelial glycoprotein (EGP-314), cytochrome C oxidase-subunit 1, ribosomal L31 protein, and ceruloplasmin were found to be differentially expressed. Specific primers were designed to study this newly reported brain EGP-314, a cellular adhesion molecule involved in cell-cell and cell-extracellular matrix interactions and related with cytoskeletal organization, differentiation, and proliferation. In the frontal and occipital lobes, EGP-314 expression was low in control and ischemic conditions and increased in sham injured conditions, whereas in the hippocampal region its expression was induced only by ischemia. In situ hybridization and immunohistochemistry revealed that EGP-314 mRNA and the protein were present in the ischemic hippocampus pyramidal neurons. DNA fragmentation was demonstrated by TUNEL and LM-PCR analysis in hippocampus region. TUNEL positive pyramidal neurons were observed at 15 min of ischemia. DNA ladder was found at 12 and 15 min of ischemia.

Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats.

Dapsone (4,4'-diaminodiphenylsulfone) is employed in the chemotherapy against leprosy. Dapsone also prevents neuronal damage induced by glutamate agonists. As glutamate excitotoxicity is implicated in the damage after ischemia, we tested the ability of dapsone to prevent ischemic injury in a model of permanent middle cerebral artery (MCA) occlusion in rats. Either dapsone (9.375 or 12.5 mg/kg doses) or vehicle were i.p. administered 30 min after occlusion. Rats from the control group showed a permanent neurological deficit after occlusion, while dapsone-treated groups improved significantly. Dapsone-treated animals showed a reduction of 93% (9.375 mg/kg dose) and 92% (12.5 mg/kg dose) in the infarction volume as compared to control values.